Stock Events

BerGenBio ASA 

$2.5
67
+$0+0% Tuesday 20:00

Statistics

Day High
-
Day Low
-
52W High
2.5
52W Low
0.03
Volume
-
Avg. Volume
0
Mkt Cap
977,178
P/E Ratio
0
Dividend Yield
-
Dividend
-

Earnings

14NovConfirmed
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Q3 2022
-1.03
-0.91
-0.79
-0.67
Expected EPS
-0.82
Actual EPS
-0.67

People Also Follow

This list is based on the watchlists of people on Stock Events who follow BRRGF. It's not an investment recommendation.
Alphabet
68918
GOOGL
Apple
60554
AAPL
Microsoft
56693
MSFT
Amazon
51850
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Incyte
INCY
Mkt Cap14.79B
Incyte Corporation focuses on the discovery, development, and commercialization of various therapeutics, including those in oncology, which competes with BerGenBio's cancer-focused pipeline.
AMGEN
AMGN
Mkt Cap177.72B
Amgen Inc. is a biotechnology company that develops and produces medicines in areas including oncology/hematology, competing directly with BerGenBio's cancer treatment developments.
Gilead Sciences
GILD
Mkt Cap90.4B
Gilead Sciences, Inc. is involved in the research, development, and commercialization of drugs in areas such as oncology, directly competing with BerGenBio's therapeutic areas.
Merck &
MRK
Mkt Cap318.55B
Merck & Co., Inc. is a global healthcare company that produces pharmaceuticals across various areas, including cancer, making it a competitor to BerGenBio.
Bristol-Myers Squibb
BMY
Mkt Cap86.44B
Bristol-Myers Squibb Company offers biopharmaceutical products, including those for cancer treatment, competing with BerGenBio's oncology focus.
Novartis
NVS
Mkt Cap232.42B
Novartis AG engages in the research, development, manufacturing, and marketing of healthcare products, including oncology, which competes with BerGenBio's product range.
Pfizer
PFE
Mkt Cap169.83B
Pfizer Inc. is a research-based global biopharmaceutical company with a broad range of products including oncology treatments, competing with BerGenBio.
Roche
RHHBY
Mkt Cap220.72B
Roche Holding AG focuses on pharmaceuticals and diagnostics in oncology, among other areas, directly competing with BerGenBio's cancer therapies.
Astrazeneca
AZN
Mkt Cap244.04B
AstraZeneca PLC is a biopharmaceutical company focusing on the discovery, development, and commercialization of prescription medicines, including for cancer, competing with BerGenBio.
Lilly(Eli) &
LLY
Mkt Cap814.94B
Eli Lilly and Company is engaged in the discovery, development, manufacture, and sale of a range of pharmaceutical products, including those for cancer, making it a competitor to BerGenBio.

About

Pharmaceuticals: Major
Health Technology
BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in development of drugs to treat immune evasive, drug resistant, and metastatic cancers; and respiratory diseases. Its lead candidate is Bemcentinib, a bio-available small molecule AXL inhibitor, which is in Phase II clinical development in major cancer indications and COVID-19. Its Phase II clinical trial program focuses on treatment of non-small cell lung cancer, acute myeloid leukaemia, and myelodysplastic syndrome, as well as COVID-19. In addition, it is developing tilvestamab, an anti-AXL antibody that is in Phase Ib clinical trial. BerGenBio ASA has a collaboration agreement with Merck & Co. for clinical trials. The company was incorporated in 2007 and is based in Bergen, Norway.
Show more...
CEO
Richard Godfrey
Employees
16
Country
NO
ISIN
NO0013251173
WKN
000A2DPC0

Listings

OTCM
US
BRRGF
F
DE
7BG0.F
OL
NO
BGBIO.OL
LSE
GB
0RU5.LSE